Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070401
Filing Date
2025-05-13
Accepted
2025-05-13 16:20:20
Documents
53
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q evok-20250331.htm   iXBRL 10-Q 1282565
2 EX-10.1 evok-ex10_1.htm EX-10.1 41863
3 EX-31.1 evok-ex31_1.htm EX-31.1 14845
4 EX-31.2 evok-ex31_2.htm EX-31.2 14962
5 EX-32.1 evok-ex32_1.htm EX-32.1 10023
6 EX-32.2 evok-ex32_2.htm EX-32.2 9999
  Complete submission text file 0000950170-25-070401.txt   5627096

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evok-20250331.xsd EX-101.SCH 889883
56 EXTRACTED XBRL INSTANCE DOCUMENT evok-20250331_htm.xml XML 797530
Mailing Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

EIN.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36075 | Film No.: 25940435
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)